630 results on '"Forst, T"'
Search Results
2. Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?: Pro
3. Kardiovaskuläre Aspekte der Diabetestherapie: Endlich Grund zur Freude für Kardiologen
4. Kardiovaskuläre Effekte von Metformin, Sulfonylharnstoffen und Gliniden
5. Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?
6. CEBRANOPADOL, A NOVEL FIRST-INCLASS ANALGESIC: EFFICACY, SAFETY, TOLERABILITY IN PATIENTS WITH PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY (DPN): WIP16–0478
7. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
8. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes
9. Insulintherapie bei Patienten mit Herzerkrankungen: Pro und Kontra
10. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease
11. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
12. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
13. Folgen des Wechselns von zweimal täglich verabreichtem Basalinsulin auf einmal täglich Insulin glargin 300 E / ml (Gla-300) bei Patienten mit Typ-1-Diabetes: Die Phase-4-Studie OPTIMIZE
14. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
15. A Diabetes Outcome and Progression Trial – Die ADOPT Studie: Mögliche Auswirkungen auf die praktische Therapie des Typ-2-Diabetes mellitus
16. Evidenzbasierte Medizin: Theoretische Grundlagen und aktueller Missbrauch zur Kosteneinsparung im Gesundheitswesen
17. Therapie der diabetischen Polyneuropathie
18. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
19. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus
20. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy
21. Response Letter to D. Singh-Franco et al.
22. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
23. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus
24. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
25. Is there an ectopic secretion of monomeric calcitonin in the human being?
26. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
27. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes
28. Intensification with prandial insulin
29. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study
30. Differentiation of adipocyte-derived adult mesenchymal stem cells into insulin expressing cells in vitro: OP72
31. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight
32. Performance of the continuous glucose monitoring system (CGMS) during development of ketosis in patients on insulin pump therapy
33. Anti-Inflammatory Power of Pioglitazone, Simvastatin and Their Combination in Non-Diabetic High Cardiovascular Risk Patients with Elevated hs CRP: 433-P
34. Association between “diabetic thick skin syndrome” and neurological disorders in diabetes mellitus
35. IRIS II study: the IRIS II score—assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes
36. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus
37. Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements*
38. Selbsttitration mit Insulin glargin 300 oder 100 E/ml führt zu verbesserter Wirksamkeit vs. arztgeführter Titration: Vergleich der Studien TAKE-CONTROL, AT.LANTUS und ATLAS bei Menschen mit Typ-2-Diabetes (T2DM)
39. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
40. Comment on: Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909–1914
41. Sequentielle Therapieeskalation mit Dapagliflozin und Saxagliptin verbessert die Insulinsekretion und den Glukagon-Insulin Quotienten im hyperglykämischen Clamp bei Patienten mit einem Diabetes mellitus Typ 2
42. Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes
43. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study
44. Repeatability of three-day dietary records in the EURODIAB IDDM Complications Study
45. Glukoseselbstmessung – technische Möglichkeiten und Limitationen
46. Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes
47. Dapagliflozin senkt den postprandialen Blutzucker ohne Anstieg von C-Peptid oder Insulin
48. Response letter to d. Singh-franco et Al
49. Intima Media Dicke - Geeigneter Biomarker für das Therapiemonitoring
50. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.